Cover: End-Stage Renal Disease and the ''Cost'' of Medical Technology

End-Stage Renal Disease and the ''Cost'' of Medical Technology

Published 1977

by Richard A. Rettig


Download eBook for Free

FormatFile SizeNotes
PDF file 2.1 MB

Use Adobe Acrobat Reader version 10 or higher for the best experience.


Purchase Print Copy

 Format Price
Add to Cart Paperback55 pages $23.00

Reviews developments since Sec. 299I of Public Law 92-603 went into effect, extending Medicare coverage for hemodialysis and renal transplantation for chronic kidney failure. This paper analyzes sources of difficulties surrounding this program, and draws out lessons having potential for other expensive, life-saving technologies. The author reviews the history of hemodialysis and renal transplantation progress, and outlines cost problems of the end-stage renal disease program including lack of accurate cost estimates at inception, failure of the program to transfer many patients to home dialysis, and failure to lower costs by advances in technology. Some lessons drawn from this experience: (1) Efforts to predict dynamics of clinical developments are likely to be wrong in important aspects. (2) R&D is needed on etiology, pathogenesis, and treatment and prevention of disease states for which there is patient treatment benefit program. (3) Policy decisions that allocate scarce resources for saving relatively few lives deserve thoughtful deliberation.

This report is part of the RAND paper series. The paper was a product of RAND from 1948 to 2003 that captured speeches, memorials, and derivative research, usually prepared on authors' own time and meant to be the scholarly or scientific contribution of individual authors to their professional fields. Papers were less formal than reports and did not require rigorous peer review.

This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit

RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.